AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00134030
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00134030
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02453282
Drug: Paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT02453282
Drug: Gemcitabine + Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT02453282
Drug: Gemcitabine + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT02453282
Drug: Pemetrexed + Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy Agents
Trial: NCT01972568
Drug: Atacicept 75 milligram (mg)
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
Trial: NCT01972568
Drug: Atacicept 150 mg
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
Trial: NCT02453282
Drug: Pemetrexed + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy Agents
Trial: NCT00002982
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002982
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002982
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002982
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002982
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002982
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03977584
Drug: Crenezumab
RxNorm normalized name: Crenezumab
DrugBank: Crenezumab (DB11959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
Trial: NCT00306189
Drug: 100 mg AMG 162
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg AMG 162 (denosumab) SC every 6 months
Trial: NCT04538040
Drug: Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine in male, 45+ year old subjects. The study will also include secondary outcomes of quality of life (QOL) and weight changes.
Trial: NCT00306189
Drug: 60 mg AMG 162
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg AMG 162 (denosumab) SC every 6 months
Trial: NCT01624766
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00306189
Drug: 14 mg AMG 162
RxNorm normalized name: AMG-222
DrugBank: AMG-222 (DB06011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg AMG 162 (denosumab) SC every 6 months
Trial: NCT03339349
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
Trial: NCT02277457
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg once daily
Trial: NCT02277457
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250 mg twice daily
Trial: NCT00990613
Drug: Dimebon IR
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
Trial: NCT00990613
Drug: Dimebon Transdermal
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Trial: NCT00370071
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
Trial: NCT00855673
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard medical treatment
Trial: NCT00062946
Drug: (18F)fallypride
RxNorm normalized name: Fludeoxyglucose (18F)
DrugBank: Fallypride (DB15167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03608579
Drug: Autologous Adipose Derived Mesenchymal Stromal Cells
RxNorm normalized name: Autologous adipose derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
Trial: NCT06081712
Drug: TNP-2198
RxNorm normalized name: TNP-2092
DrugBank: TNP-2092 (DB16312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Trial: NCT04707326
Drug: Dolutegravir / Lamivudine Pill
RxNorm normalized name: dolutegravir / lamiVUDine Pill
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B
Trial: NCT00990613
Drug: Dimebon Transdermal
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Trial: NCT02741856
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For more information please see the arm descriptions section.
Trial: NCT02741856
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For more information please see the arm descriptions section.
Trial: NCT02741856
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For more information please see the arm descriptions section.
Trial: NCT02762578
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice daily subcutaneous (sc, under the skin) injection.
Trial: NCT04185246
Drug: NH002 (Perflutren Lipid Microspheres) Injectable Suspension
RxNorm normalized name: propofol lipid emulsion Injectable Suspension
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.
Trial: NCT02762578
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice daily subcutaneous (sc, under the skin) injection.
Trial: NCT03628209
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
Trial: NCT03628209
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m\^2. Dose level 3: 75 mg/m\^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
Trial: NCT04735822
Drug: Part 1: Belumosudil 40 mg/mL Sequence FAEBDC
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence GHI
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence HIG
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence IGH
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence IHG
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence GIH
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)
Trial: NCT04735822
Drug: Part 2: Belumosudil 200 mg Sequence HGI
DrugBank: Belumosudil (DB16703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)
Trial: NCT00670501
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Trial: NCT00670501
Drug: teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Trial: NCT04678856
Drug: Dupilumab SAR231893
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Trial: NCT00670501
Drug: Vitamin D Supplement
RxNorm normalized name: Vitamin D supplement
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
Trial: NCT01345136
Drug: RAD001, everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Trial: NCT04548583
Drug: Remestemcel-L
RxNorm normalized name: remestemcel-L
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
Trial: NCT01488279
Drug: Dexamethasone 2.5 mg and Sitagliptin 100 mg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
Trial: NCT01488279
Drug: Dexamethasone 2.5 mg and placebo tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
Trial: NCT00990613
Drug: Dimebon Transdermal
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
Trial: NCT02236403
Drug: Ivermectin 0.1% Metronidazole 1%
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05720572
Drug: Antazoline
RxNorm normalized name: Antazoline
DrugBank: Antazoline (DB08799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants assigned to the antazoline group will be administered antazoline in boluses in boluses of 100 mg diluted to 20 cm3 every 10 minutes up to a total dose of 300 mg diluted to 60 cm3 or conversion of AF to SR. Drug administration will also be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Trial: NCT05720572
Drug: Propafenone
RxNorm normalized name: Propafenone
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to the propafenone group were administered three 20-cm3 boluses every 10 minutes up to 60 cm3 or conversion of AF to SR. Each of the first two boluses included 70 mg propafenone (total dose 140 mg), and the third bolus contained only 20-cm3 0.9% NaCl. Drug administration will be stopped in case of an adverse event or conversion of AF to a different supraventricular arrhythmia. BP will be measured before every injection.
Trial: NCT04978025
Drug: Colloidal Silver
RxNorm normalized name: COLLOIDAL SILVER
DrugBank: Silver (DB12965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
Trial: NCT00624481
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20ug subcutaneous injection daily for 24 weeks
Trial: NCT00624481
Drug: Teriparatide Nasal Spray
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: teriparatide intranasally daily for 24 weeks
Trial: NCT02421471
Drug: Ingenol mebutate 0.015 percent or 0.05 percent gel
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
Trial: NCT03113071
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine will be administered in combination with Digoxin
Trial: NCT03113071
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine will be administered in combination with Digoxin
Trial: NCT01602120
Drug: Lampalizumab
RxNorm normalized name: Lampalizumab
DrugBank: Lampalizumab (DB11826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
Trial: NCT03822468
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib (at a dosage of 400 mg or 600 mg) QD orally taken on days 1 to 21 of a 28-day cycle, followed by 7 days off ribociclib (days 22 to 28). Ribociclib is supplied as 200 mg tablets as individual patient supply packaged bottles.
Trial: NCT03822468
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg tablets for oral use QD continuously
Trial: NCT05736081
Drug: Intravitreal dexamethasone implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal implant of dexamethasone 0.7 mg with previous topic anesthesia and iodine drops
Trial: NCT00567372
Drug: bevacizumab (Sub-tenon´s injection)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
Trial: NCT02866916
Drug: SXL01
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment will be administered continuously over 24h through the subcutaneous route.
Trial: NCT01784445
Drug: Ceftazidime
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
Trial: NCT00863525
Drug: odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
Trial: NCT00182091
Drug: Recombinant human growth hormone
RxNorm normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
Trial: NCT00182091
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To maintain study-subject blinding, doses were sham adjusted.
Trial: NCT00630565
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
Trial: NCT00630565
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m\^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
Trial: NCT00630565
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
Trial: NCT00768183
Drug: KADIAN Capsule + water (under fasting conditions)
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules 100mg + 240 mL in 4 shots of 60 mL
Trial: NCT00768183
Drug: morphine sulfate IR oral solution + water
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate IR oral solution + water (under fasting conditions)
Trial: NCT03822468
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg tablets for oral use QD continuously
Trial: NCT00028782
Drug: etanidazole
RxNorm normalized name: Etanidazole
DrugBank: Etanidazole (DB12736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01010373
Drug: AS101
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg/m2 AS101 will be given intravenously (IV) three times per week.
Trial: NCT03822468
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
Trial: NCT01787331
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02686840
Drug: sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~* Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~* Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~* A specimen bottle to collect the POC if passed out.~* Two pairs of disposable gloves.~* Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception